Amneal Pharmaceuticals, Inc.

Amneal Pharmaceuticals, Inc. (the Company , we, us, or our ) is a diversified, global biopharmaceutical company that develops, manufactures, markets, and distributes a diverse portfolio of essential medicines. Our Affordable Medicines segment includes retail generics, injectables, and biosimilars. In our Specialty segment, we offer a portfolio of branded pharmaceuticals focused primarily on central nervous system and endocrine disorders. Through our AvKARE segment, we are a distributor of pharmaceuticals and other products for the U.S. federal government, retail, and institutional markets. We operate principally in the United States ( U.S. ), India, and Ireland. Refer to the section Segments of the Business below for an overview of our segments. Corporate Structure We are a holding company, whose principal assets are common units (the Amneal Common Units ) of Amneal Pharmaceuticals, LLC ( Amneal ). Immediately prior to the Reorganization (as defined herein), we held 50.4% of the Amneal Common Units and the group, together with their affiliates and certain assignees, who owned Amneal when it was a private company (the Members or the Amneal Group ) held the remaining 49.6%. On November 7, 2023, we implemented a plan pursuant to which the Company and Amneal reorganized and simplified our corporate structure by eliminating our umbrella partnership-C-corporation structure and converting to a more traditional C-corporation structure whereby all stockholders hold their voting and economic interests directly through the public company (the Reorganization ).